DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ZOMETA

Summary for Tradename: ZOMETA

Patents:2
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 ZOMETA

Pharmacology for Tradename: ZOMETA

Ingredient-typeDiphosphonates
Drug ClassBisphosphonate

Clinical Trials for: ZOMETA

Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Zométa
Status: Terminated Condition: Giant Cell Tumors of Bone

PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
Status: Active, not recruiting Condition: Prostate Cancer

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Status: Active, not recruiting Condition: Breast Cancer

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
Status: Completed Condition: Prostate Cancer

ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases
Status: Terminated Condition: Prostate Cancer

Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis
Status: Completed Condition: Metastatic Breast Cancer; Bone Metastases

Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer
Status: Completed Condition: Breast Neoplasms

Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
Status: Terminated Condition: Malignant Pleural Effusion; Non Small Cell Lung Cancer

Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®
Status: Completed Condition: Paget's Disease of the Bone; Hypocalcemia

Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
Status: Terminated Condition: Adenocarcinoma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
ZOMETA
zoledronic acid
INJECTABLE;IV (INFUSION)021223Aug 20, 2001DISCNNo<disabled><disabled>
Novartis
ZOMETA
zoledronic acid
INJECTABLE;IV (INFUSION)021223Jun 17, 2011RXYes7,932,241<disabled>Y<disabled>
Novartis
ZOMETA
zoledronic acid
INJECTABLE;IV (INFUSION)021223Jun 17, 2011RXYes8,324,189*PED<disabled>Y<disabled>
Novartis
ZOMETA
zoledronic acid
INJECTABLE;IV (INFUSION)021223Mar 7, 2003RXYes8,324,189*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ZOMETA

Drugname Dosage Strength RLD Submissiondate
zoledronic acidInjection4 mg/100 mg, 100 mL vialZometa1/31/2012
zoledronic acidInjection0.8 mg (base) /mLZometa6/11/2008

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc